Search Results - "De Oliveira, Claudia H."

Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment by Qosa, Hisham, de Oliveira, Claudia H. M. C., Cizza, Giovanni, Lawitz, Eric J., Colletti, Nicholas, Wetherington, Jeffrey, Charles, Edgar D., Tirucherai, Giridhar S.

“…BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific…”
Get full text

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity by Cheng, Dong, Zinker, Bradley A., Luo, Yi, Shipkova, Petia, De Oliveira, Claudia H., Krishna, Gopal, Brown, Elizabeth A., Boehm, Stephanie L., Tirucherai, Giridhar S., Gu, Huidong, Ma, Zhengping, Chu, Ching-Hsuen, Onorato, Joelle M., Kopcho, Lisa M., Ammar, Ron, Smith, Julia, Devasthale, Pratik, Lawrence, R. Michael, Stryker, Steven A., Dierks, Elizabeth A., Azzara, Anthony V., Carayannopoulos, Leon, Charles, Edgar D., Lentz, Kimberley A., Gordon, David A.

“…Monoacylglycerol acyltransferase 2 (MGAT2) is an important enzyme highly expressed in the human small intestine and liver for the regulation of triglyceride…”
Get full text

Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis by Charriez, Christina M., Zhang, Sandra, de Oliveira, Claudia H.M.C., Patel, Vrunda, Oh, Young S., Hirano, Ikuo, Schoepfer, Alain, Dellon, Evan S.

“…Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition that interferes with normal food ingestion, negatively impacting quality of…”
Get full text

Su1285 IMPLICATIONS FOR NON-INVASIVE BIOMARKERS OF EOSINOPHILIC ESOPHAGITIS BASED ON RESULTS FROM A PHASE 2 TRIAL OF CENDAKIMAB IN ATOPIC DERMATITIS by Dellon, Evan S., Li, Jie, Harris, Sarah, Gao, Lu, De Oliveira, Claudia H., Charriez, Christina M., Silverberg, Jonathan

Get full text

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial by Blauvelt, Andrew, Guttman-Yassky, Emma, Lynde, Charles, Khattri, Saakshi, Schlessinger, Joel, Imafuku, Shinichi, Tada, Yayoi, Morita, Akimichi, Wiseman, Marni, Kwiek, Bartlomiej, Machkova, Martina, Zhang, Peijin, Linaberry, Misti, Li, Jie, Zhang, Sandra, Franchin, Giovanni, Charles, Edgar D, De Oliveira, Claudia H M C, Silverberg, Jonathan I

“…Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors…”
Get more information

Distribution of HOMA-IR in Brazilian subjects with different body mass indexes by Ghiringhello, Maria T, Vieira, José Gilberto H, Tachibana, Teresinha T, Ferrer, Cláudia, Maciel, Rui M B, Amioka, Patrícia H C, Hauache, Omar M, de Oliveira, Cláudia H M C, Khawali, Cristina, Reis, André F

Get full text

Continuous glucose monitoring: a critical appraisal after one year experience by Oliveira, Cláudia H M C de, Berger, Karina, Souza, Sílvia Coral de A L E, Marui, Suemi, Khawali, Cristina, Hauache, Omar M, Vieira, José Gilberto H, Maciel, Rui M B, Reis, André F

“…Conventional assessment of glycemic control in diabetes mellitus (DM) includes blood glucose attention to glycemia and glycated hemoglobin levels. Recently, we…”
Get full text